The T1D community has been clear: deceased donor islets (DDIs) must be accessible for those who qualify. Earlier this year, Breakthrough T1D went to work, submitting a proposal to the Department of Health and Human Services (HHS) and meeting with FDA and the Health Resources and Services Administration to urge a change. Today we’re seeing real, tangible movement. HHS published a Request for Information on potential changes to the regulation of deceased donor islets—the first step toward a policy change. In other words, they want to hear from you. Read the RFI and submit your comments here. Look for the comment button on the top left of the page: regulations.gov/document/FDA…

The Food and Drug Administration is a critical partner in accelerating cures and therapies for type 1 diabetes. The nominee to run FDA knows first-hand how important that is. Dr. Heidi Overton, nominee to be the next FDA Commissioner, has shared with us that she lives with type 1 diabetes.

Breaking news: for the first time in 30 years, there’s a new approved therapy for kidney disease in T1D. Today, the FDA approved finerenone (brand name Kerendia) to treat chronic kidney disease (CKD) associated with T1D. CKD is one of the most common complications of T1D—nearly one-third of people living with T1D will develop it, raising their risk of kidney failure and cardiovascular disease. Until now, their options were limited. Breakthrough T1D strategically collaborated with Bayer to support the FINE-ONE trial behind this approval. As we drive toward curing T1D, we help make everyday life better for the people who face it—starting today. Read what this approval means for the T1D community at the link below! bit.ly/4h89WUF

De la Detección Temprana a la Investigación Clínica: Avances en Diabetes Tipo 1 nitter.net/i/broadcasts/1RKZzBnDw…

Last March, Breakthrough T1D sent a proposal to the Department of Health and Human Services (HHS) to reclassify deceased donor islets (DDIs) as organs rather than drugs. After months of engagement across HHS, the department has taken action. Today, the Food and Drug Administration (FDA) sent a request for information (RFI) to the Office of Management and Budget (OMB) for review titled “Improving Patient Access to Deceased Donor Islet Cells and Cell Products”. This is the first step in making deceased donor islets more accessible to those in the T1D community who qualify for transplants. We applaud HHS, FDA and the Health Resources and Services Administration (HRSA) for acting on this important topic. Follow Breakthrough T1D for updates on when this RFI is published so that you can make your voice heard.

Until now, clinicians have lacked concrete guidance on who, when, and how to screen for type 1 diabetes (T1D). Led by Breakthrough T1D, experts around the globe have provided practical guidance for screening. Learn more here: bit.ly/3SHCfRT

If you or a loved one lives with type 1 diabetes (T1D) and has been impacted by Hurricane Lowell, visit the link below to learn more about available resources! Stay safe! 💙 bit.ly/3BeTUaf

Applications for Breakthrough T1D 2027 Children's Congress are now OPEN! If you are passionate about advocacy, live with T1D, and are between the ages of 4 and 17, apply for this once-in-a-lifetime experience at cc.BreakthroughT1D.org. Selected Delegates will help make a difference for everyone living with T1D by taking their stories to lawmakers on Capitol Hill next summer. #BreakthroughT1DCC27

An exciting step forward for cell therapies! Swipe to learn the latest, and be sure to stay tuned to learn more! Want to learn more about the research we’re funding? Visit the link below! bit.ly/4qVz84E

Thank you, Representatives @RepDianaDeGette, @RepMMM, @RepKimSchrier, @RepBresnahan, and @RepAngieCraig for leading the charge in the House on insulin affordability by introducing the bipartisan INSULIN Act of 2026. Insulin isn’t a choice; it’s a necessity. That’s why Breakthrough T1D has long championed efforts to make insulin both accessible and affordable for the over 1.5 million Americans who depend on it. While progress has been made capping costs in some cases, it will take an act of Congress to ensure that affordable access is a reality for all. That’s what the INSULIN Act aims to do. This bill (like its companion in the Senate) would cap the out-of-pocket costs of insulin at $35 dollars per month for private health insurance plans, delivering real relief to individuals and families who have no choice but to pay whatever price their insurance requires. In July, after nearly 30,000 emails were sent from Breakthrough T1D advocates to their Senators, a bipartisan group of Senators voted the INSULIN Act out of committee. Now we need similar progress in the House to get the INSULIN Act passed by year’s end. Urge your Representative to become a cosponsor today at the link below! bit.ly/4gJSJlL

Clinical trials are bringing us closer to curing type 1 diabetes! Over the weekend, the Breakthrough T1D Northern California team hosted a Community Summit panel with Dr. Piotr Witkowski (University of Chicago), Dr. Gary Meininger (Sana Biotechnology), and moderator Karen Jordan, Chair of our International Board of Directors, to discuss the real progress we're making. “Being at this Community Summit was inspiring and provides all of us further energy and drive to help bring potential curative therapies as quickly and safely as possible to all individuals with T1D who could benefit.” - Dr. Gary Meininger Community Summits are a great way to connect with your local T1D community and to the research driving us forward. Find one near you breakthrought1d.org/t1d-comm…

The U.S Food and Drug Administration has authorized Abbott's Libre Duo 10 Day, a two-in-one sensor to monitor glucose and ketones. Visit the link below to learn more! bit.ly/4hWmwso

We’re partnering across HHS to support the T1D community! Today, Breakthrough T1D leaders - including CEO Aaron Kowalski, Chief Global Advocacy Officer Lynn Starr, CSO Sanjoy Dutta, CMO Thomas Danne , and Campbell Hutton, SVP, Global Advocacy - met with senior leadership of the FDA. They discussed the unmet needs of the T1D community and highlighted the necessity of a robust FDA to quickly and safely deliver next-generation cures and therapies currently in development. Separately, the leadership team met with the Health Resources and Services Administration, HHS - the agency responsible for the organ transplant system. Breakthrough T1D advocated for reclassifying deceased donor cells as organs, placing them under HRSA’s oversight to expand accessibility for qualifying transplant candidates. With innovators actively advancing T1D cures, collaborating across HHS, the FDA, and HRSA ensures we are ready to efficiently test and approve incoming therapies to ultimately end this disease. Breakthrough T1D Advocacy Read the full statement here: breakthrought1d.org/for-the-…

We’re recruiting our next class of Delegates, ages 4-17, for 2027 Children’s Congress! Those selected to attend the event will help make a difference for everyone living with T1D by taking their stories to lawmakers and officials in Washington, DC. It all starts with an information session August 13, 7 pm ET. We hope you’ll join us to learn about the program, how to apply, and what to expect if you are selected. Register now to learn how you can help make a difference for the T1D community! breakthrought1d-org.zoom.us/…

Our thoughts are with everyone who has been impacted by the devastating fires in Washington state. If you or a loved one lives with type 1 diabetes (T1D), visit the link below to find resources. Stay safe! 💙 bit.ly/3BeTUaf

Diabetes Tipo 1 en el Entorno Escolar nitter.net/i/broadcasts/1pKdRRErO…

Today, we hit a major milestone in the fight for insulin affordability! The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee just voted to advance the INSULIN Act, bringing us one step closer to making accessible, affordable insulin a reality for all. Thank you to the Senate champions and our countless advocates whose voices and support helped get us here! Read our full statement here: bit.ly/4wV6uTF